{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:59:54Z","timestamp":1792688394819,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.msard.2025.106885","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:42:44Z","timestamp":1764117764000},"page":"106885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-8727","authenticated-orcid":false,"given":"Helmut","family":"Butzkueven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van Der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Van Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Grand-Maison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis Sanchez","family":"Menoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ramo-Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Skromne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan Muros-Le","family":"Rouzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106885_bib0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ncl.2023.06.003","article-title":"Leveraging real-world evidence and observational studies in treating multiple sclerosis","volume":"42","author":"Aboseif","year":"2024","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2025.106885_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104941","article-title":"Real world study of ocrelizumab in multiple sclerosis: Kuwait experience","volume":"79","author":"Alroughani","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106885_bib0003","series-title":"Presented at ECTRIMS 2024, Sep 17 - Sep 20","article-title":"Early treatment with ocrelizumab: a multicentre, real-world observational study","author":"Alvarez","year":"2024"},{"key":"10.1016\/j.msard.2025.106885_bib0004","series-title":"Presented at 9th Joint ECTRIMS-ACTRIMS meeting. October 11-13","article-title":"Persistence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in the German NeuroTransData registry","author":"Braune","year":"2023"},{"issue":"8","key":"10.1016\/j.msard.2025.106885_bib0005","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106885_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1564327","article-title":"CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany","volume":"16","author":"Buttmann","year":"2025","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106885_bib0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106885_bib0008","series-title":"Abstract presented at: 2023 American Academy of Neurology (AAN) Annual Meeting; April 22-27","article-title":"Long-term treatment with first-line ocrelizumab in patients with early RMS: 9-year OPERA subgroup analysis","author":"Cerqueira","year":"2023"},{"issue":"1","key":"10.1016\/j.msard.2025.106885_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106885_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106885_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105570","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real-world experience of two Swiss multiple sclerosis centers","volume":"86","author":"Diem","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106885_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106885_bib0014","series-title":"presented at ECTRIMS 2024; Sep 17-20","article-title":"10 Years of ocrelizumab treatment in multiple sclerosis: long-term efficacy and safety clinical trial data","author":"Hauser","year":"2024"},{"issue":"3","key":"10.1016\/j.msard.2025.106885_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.msard.2025.106885_bib0016","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2025.106885_bib0017","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106885_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40940-w","article-title":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials","volume":"13","author":"Ingwersen","year":"2023","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.msard.2025.106885_bib0019","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1177\/1352458516653667","article-title":"Observational data: understanding the real MS world","volume":"22","author":"Kalincik","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106885_bib0020","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-023-11943-4","article-title":"Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension","volume":"271","author":"Kappos","year":"2024","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106885_bib0021","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","article-title":"Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario","volume":"45","author":"Lorefice","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106885_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/11795735241260563","article-title":"Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: a propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments","volume":"16","author":"Muros-Le Rouzic","year":"2024","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2025.106885_bib0023","series-title":"Summary of Product Characteristics","year":"2022"},{"key":"10.1016\/j.msard.2025.106885_bib0024","series-title":"Prescribing Information","year":"2024"},{"issue":"1","key":"10.1016\/j.msard.2025.106885_bib0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","article-title":"Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis","volume":"11","author":"Pardo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2025.106885_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/ene.15142","article-title":"Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study","volume":"29","author":"Pontieri","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106885_bib0027","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction versus escalation in multiple sclerosis: a 10-year real world study","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.msard.2025.106885_bib0028","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"MSBase Study GroupDanish MS Registry Study Group. Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106885_bib0029","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/13524585241267211","article-title":"Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis","volume":"30","author":"Roos","year":"2024","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2025.106885_bib0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106885_bib0031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis\u2014Insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106885_bib0032","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106885_bib0033","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106885_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.863105","article-title":"Safety, adherence and persistence in a real-world cohort of German MS patients newly treated with ocrelizumab: first insights from the CONFIDENCE study","volume":"13","author":"Weber","year":"2022","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106885_bib0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106885_bib0036","first-page":"1330","article-title":"Comparing switch to ocrelizumab,cladribine or natalizumab after fingolimod treatment cessation in multiplesclerosis","volume":"93","author":"Zhu","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106885_bib0037","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12916-016-0627-1","article-title":"The importance of collecting structured clinical information on multiple sclerosis","volume":"14","author":"Ziemssen","year":"2016","journal-title":"BMC. Med."}],"updated-by":[{"DOI":"10.1016\/j.msard.2026.107131","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000}},{"DOI":"10.1016\/j.msard.2026.107131","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:50:10Z","timestamp":1781509810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S2211034825006236"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106885","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106885"}}